OTC Markets OTCPK - Delayed Quote USD

Silence Therapeutics plc (SLNCF)

0.5000

-0.2600

(-34.21%)

As of April 14 at 10:22:43 AM EDT. Market Open.

Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven?

Silence Therapeutics plc ( NASDAQ:SLN ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. 13 days ago

SLN
+3.32%
SLNCF
-34.21%
Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)

Today is shaping up negative for Silence Therapeutics plc ( NASDAQ:SLN ) shareholders, with the analysts delivering a...

Simply Wall St. last month

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

LONDON, March 05, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET.

Business Wire last month

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

SLNCF
-34.21%
Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Silence Therapeutics ( NASDAQ:SLN ) Full Year 2024 Results Key Financial Results Revenue: UK£43.3m (up 71% from FY...

Simply Wall St. last month

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

LONDON, February 27, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update.

Business Wire last month

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

LONDON, February 13, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025.

Business Wire last month

SLN
+3.32%
SLNCF
-34.21%
Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Key Insights Given the large stake in the stock by institutions, Silence Therapeutics' stock price might be vulnerable...

Simply Wall St. 3 months ago

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

We recently compiled a list of the 10 Oversold Global Stocks To Buy Right Now. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against the other oversold global stocks. ‘There are decades where nothing happens, and there are weeks where decades happen” is apt when starting a […]

Insider Monkey 3 months ago

SLNCF
-34.21%
^FTSE
Insider Traders Lose UK£124k As Silence Therapeutics Drops

Insiders who bought UK£187.6k worth of Silence Therapeutics plc's ( NASDAQ:SLN ) stock at an average buy price of...

Simply Wall St. 3 months ago

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

LONDON, December 09, 2024--Silence Therapeutics plc ("Silence" or the "Company") (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California.

Business Wire 4 months ago

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

LONDON, November 26, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 10:00 a.m. ET.

Business Wire 4 months ago

SLN
+3.32%
SLNCF
-34.21%
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.

Zacks 4 months ago

SLNCF
-34.21%
AMGN
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented at the American Heart Association (AHA) Scientific Sessions. Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted redu

Benzinga 4 months ago

SLNCF
-34.21%
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

LONDON, November 18, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were prese

Business Wire 4 months ago

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Silence Therapeutics ( NASDAQ:SLN ) Third Quarter 2024 Results Key Financial Results Revenue: UK£1.14m (down 59% from...

Simply Wall St. 4 months ago

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

LONDON, November 14, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights.

Business Wire 4 months ago

SLN
+3.32%
SLNCF
-34.21%
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LONDON, November 13, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20th at 2:00 p.m. GMT.

Business Wire 4 months ago

SLN
+3.32%
SLNCF
-34.21%
Is Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical industry remains a hub of […]

Insider Monkey 5 months ago

SLNCF
-34.21%
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Silence...

Simply Wall St. 5 months ago

SLN
+3.32%
SLNCF
-34.21%

Performance Overview

Return	SLNCF	S&P 500 (^GSPC)
YTD	-80.95%	-7.64%
1-Year	-93.75%	+7.32%
3-Year	-92.32%	+23.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Silence Therapeutics plc (SLNCF)

Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven?

Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

Insider Traders Lose UK£124k As Silence Therapeutics Drops

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Is Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?

We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely

Performance Overview